Overview
© 202 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. Al rights reserved. © 202 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights.
Key Information
Al rights reserved.SGLT-2 inhibitors, GLP-1 receptor agonists, and a non-steroidal mineralocorticoid receptor are al showing promise in the prevention and management of diabetic kidney disease.New developments and clinical trials in SGLT-2 inhibitors and GLP-1 receptor agonists are showing promise for the treatment of patients with diabetic kidney disease as a result of type 2 diabetes. Continued developments in this space could lead to more personalized care, acording to research published in BMC Medicine.Diabetic kidney disease is the most comon cause of kidney failure and end-stage kidney disease worldwide and wil develop in nearly half of al patients with type 2 diabetes.
Aditionaly, it is a leading cause of cardiovascular disease and overal mortality individuals with diabetes. With the incidence of type 2 diabetes continuing to rise, early detection and management of diabetic kidney disease is esential.In a new review, investigators aimed to provide a comprehensive clinical update for diabetic kidney disease in patients with type 2 diabetes, with a specific focus on new treatment modalities.
Summary
Several strategies exist to help prevent the development of diabetic kidney disease and slow its progresion, in adition to healthy lifestyle changes. Curent goals for patients with type 2 diabetes include managing glycemic control, controling blod presure, managing cholesterol levels, and implementing lifestyle changes.SGLT-2 inhibitors have shown particular promise. Two double-blind, randomized, placebo-controled trials (CREDENCE and DAPA-CKD) have included kidney disease endpoints as the primary outcome, acording to the study.In the CREDENCE trial, participants asigned to receive canagliflozin had a 30% reduced risk of the primary kidney composite outcom